Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel
NASDAQ:CING

Cingulate Q1 2025 Earnings Report

Cingulate logo
$4.82 -0.11 (-2.25%)
As of 01:19 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cingulate EPS Results

Actual EPS
-$1.04
Consensus EPS
-$1.00
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Cingulate Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cingulate Announcement Details

Quarter
Q1 2025
Date
5/8/2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Cingulate's Q2 2026 earnings is estimated for Tuesday, August 18, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Cingulate's Q1 2025 Press ReleasePress Release
(8-K)
Cingulate's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Cingulate Earnings Headlines

Cingulate Gains Key U.S. Patent for Lead ADHD Drug
 |  tipranks.comhttps://www.tipranks.com/news/company-announcements/cingulate-gains-key-u-s-patent-for-lead-adhd-drug?utm_source=marketbeat.com&utm_medium=referral
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
June 16 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/16/3312491/0/en/cingulate-issued-first-u-s-patent-for-lead-adhd-asset-ctx-1301.html
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.tc pixel
June 16 at 1:00 AM  |  Porter & Company (Ad)
Insider Makes Bold Move With Major Cingulate Inc. Stock Purchase
June 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/insider-makes-bold-move-with-major-cingulate-inc-stock-purchase-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
FDA rejects Cingulate's application for ADHD medicine
June 3, 2026  |  bizjournals.comhttps://www.bizjournals.com/kansascity/news/2026/06/02/cingulate-adhd-declined-by-fda.html
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues
June 3, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/fda-declines-to-approve-cingulate-s-adhd-treatment-over-manufacturing-issues/ar-AA24E15l
See More Cingulate Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CING), a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

View Cingulate Profile
Earnings Tools